Symbols

BEAT

HeartBeam·NASDAQ

--(--)

BEAT fundamentals

BEAT Q4 2025 Earnings

HeartBeam (BEAT) released its earnings on Mar 12, 2026: revenue was 0 (YoY --), met estimates; EPS was -0.14 (YoY +22.22%), missed estimates.

Revenue / YoY

EPS / YoY

-0.14

+22.22%

Report date

Mar 12, 2026

BEAT Earnings Call Summary for Q4,2025

FDA Clearance and Launch: 12-lead ECG synthesis software cleared, with commercial launch targeting 150,000+ high-net-worth patients at $500-$1,000/year.
Heart Attack Detection: Pilot study in Europe aims to validate accuracy, with pivotal FDA study pending results.
12-Lead Patch Disruption: Prototype shows 86% physician support for shifting 61% of patch prescriptions, targeting $2B market.
AI Collaboration: Mount Sinai partnership to develop predictive algorithms, enhancing device clinical utility.
Financial Discipline: $14M annual operating cash outflow, $4.4M cash reserves, and 2026 breakeven at 30,000 patients.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

HeartBeam (BEAT) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

HeartBeam (BEAT)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

HeartBeam (BEAT)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

HeartBeam (BEAT)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown